Pelthos Therapeutics To Present At The Piper Sandler 37Th Annual Healthcare Conference
Institutional investors interested in scheduling an in-person one-on-one meeting with Mr. Plesha should contact their Piper Sandler representative.
For those unable to attend the Conference in person, a live webcast of the fireside chat will be available on the News & Events page in the Investors section of the Company's website at and can also be found at approximately two hours after the fireside chat.
About Pelthos Therapeutics
Pelthos Therapeutics is a biopharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens. The company's lead product ZELSUVMITM (berdazimer) topical gel, 10.3%, for the treatment of molluscum contagiosum, was approved by the U.S. Food and Drug Administration in 2024. More information is available at . Follow Pelthos on LinkedIn and X.
Contacts
Investors:
LifeSci Advisors, LLC
Mike Moyer, Managing Director
...
Media:
KWM Communications
Kellie Walsh
...
(914) 315-6072

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.

Comments
No comment